Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00006377
Status:
COMPLETED
Last Update Posted:
2013-06-18
First Post:
2000-10-04
Brief Title:
Doxorubicin Paclitaxel and Carboplatin in Treating Patients With Primary Stage III Stage IV or Recurrent Endometrial Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
Phase II Study of Sequential Administration of Doxorubicin Paclitaxel and Carboplatin in Patients With Advanced and Recurrent Endometrial Cancer
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die Combining more than one drug may kill more tumor cells
PURPOSE Phase II trial to study the effectiveness of combining doxorubicin paclitaxel and carboplatin in treating patients who have primary stage III stage IV or recurrent endometrial cancer
PURPOSE Phase II trial to study the effectiveness of combining doxorubicin paclitaxel and carboplatin in treating patients who have primary stage III stage IV or recurrent endometrial cancer
Detailed Description:
OBJECTIVES
Determine the response rate and duration of response in patients with primary stage III or IV or recurrent endometrial cancer treated with sequential doxorubicin paclitaxel and carboplatin
OUTLINE Patients receive sequential chemotherapy comprised of doxorubicin IV once every 2 weeks for 3 courses followed by paclitaxel IV over 1 hour once weekly for 9 courses and then carboplatin IV once every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL A total of 18-46 patients will be accrued for this study
Determine the response rate and duration of response in patients with primary stage III or IV or recurrent endometrial cancer treated with sequential doxorubicin paclitaxel and carboplatin
OUTLINE Patients receive sequential chemotherapy comprised of doxorubicin IV once every 2 weeks for 3 courses followed by paclitaxel IV over 1 hour once weekly for 9 courses and then carboplatin IV once every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL A total of 18-46 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-G00-1860 | Registry Identifier | PDQ Physician Data Query | None |
| CDR0000068251 | REGISTRY | None | None |